four years after a miss in a phase 3 trial put the future of the drug in doubt. Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback